About this Summit
-
The ASCO Direct™ LatAm Summit is planned to be a yearly Latin American Scientific Summit in specific oncology areas of interest (adapting every year according to that moment’s educational needs), licensed by the American Society of Clinical Oncology (ASCO®), one of the largest and most respected Medical Societies in the world, and leader in the field of Oncology.
-
This first Summit will take place in Mexico City, in the subsequent years will be hosted in other Latin American cities, and this first Summit will have the Mexican Society of Clinical Oncology as Scientific Partner
-
2024 topics: covering most recent scientific advances by the American Society of Clinical Oncology (ASCO), in the following areas:
-
Breast cancer
-
Lung cancer
-
Gastrointestinal cancer
-
Why should you attend?
-
All lectures in this Summit will be presented by the original international speakers from ASCO official conferences.
-
Live streaming (and on demand) to all Latin American countries. On-demand content will be available for 6 months after the Summit
-
Audio in Spanish, English and Portuguese.
-
The Consejo Mexicano de Oncología has accredited this educational program with 22 certification points
Scientific Agenda
-
Scientific agenda:
-
See complete agenda below
-
-
Round tables in each cluster:
-
ASCO speakers and LatAm experts appointed & coordinated by SMEO will discuss the scientific content and its impact in LatAm reality
-
Scientific Committee
Chairman
SMEO LatAm Experts Coordinating Committee
Where & when
-
September 3-5, 2024
-
WTC Mexico City: Live event
-
Live Streaming: all Latin American countries
-
Sept. 3: registration, pre symposium
-
Sept. 4: scientific sessions all day
-
Sept. 5: scientific sessions in the morning, adjournment afternoon
Scientific Agenda
-
September 3, 2024:
-
3:00-3:15 Inauguration
-
3:15-3:45 Use of circulating tumor DNA in GI cancers. Dr. Scott Kopetz
-
3:45-4:00 Q&A
-
4:00-4:30 New targets and therapeutic opportunities in metastatic colorectal cancer. Dr. Josep Tabernero
-
4:30-4:45 Q&A
-
4:45-5:05 Break
-
5:05-5:35 Evolving therapy of esophageal and GEJ. Dr. Ajani Jafer
-
5:35-5:50 Q&A
-
5:50-6:20 Strategies for treatment of liver limited metastatic disease in colorectal cancer. Dr. Scott Kopetz
-
6:20-6:35 Q&A
-
6:35-7:05 New immunotherapy strategies for microsatellite stable (MSS) colorectal cancer. Dr. Josep Tabernero
-
7:05-7:20 Q&A
-
-
September 4, 2024:
-
-
9:00-9:30 Novel targets in gastric and esophageal adenocarcinoma. Dr. Ajani Jafer
-
9:30-9:40 Q&A
-
9:40-10:40 Round Table GI Cancer: Drs. Kopetz, Tabernero, Jafer and LatAm oncologists: Dr. Laura Torrecillas and Dr. Erika Ruiz (both from Mexico)
-
10:40-11:00 Break
-
11:00-11:30 Targeted Therapy for early stage NSCLC. Dra. Enriqueta Felip
-
11:30-11:40 Q&A
-
-
-
11:40-12:10 Locally advanced NSCLC: Results from LAURA, PACIFIC 1 & 2 Clinical Trials. Dr. Ramalingam Suresh
-
12:10-12:20 Q&A
-
12:20-12-50 Perioperative Immunotherapy for NSCLC. Dr. Luis Raez
-
12:50-13:00 Q&A
-
13.00-15:00 Lunch
-
15:00-15:30 Lung Cancer: First Line Immunotherapy for metastatic disease. Dr. Ramalingam Suresh
-
-
September 4, 2024 (continued):
-
15:30-15:40 Q&A
-
15:40-16:10 Antibody Drug Conjugates (ADCs) and other options after Immunotherapy failure in NSCLC. Dr. Enriqueta Felip
-
16:10-16:20 Q&A
-
16:20- 16:50 Metastatic NSCLC: Updates in Targeted Therapy (EGFR, ALK, ROS, RET, KRAS, NTRK). Dr. Luis Raez
-
16:50-17:00 Q&A
-
17:00-17:20 Break
-
17:20-18:20 Round Table Lung Cancer with Drs. Felip, Ramalingam, Raez and LatAm oncologists: Dr. Oscar Arrieta (Mexico) and Dr. Claudio Martin (Argentina)
-
18:20-18:50 Highlights of ASCO – Neo Adjuvant treatment in locoregional breast cancer. Dr. Javier Cortes
-
18:50-19:00 Q&A
-
-
September 5, 2024:
-
9:00-9:30 Pregnancy and fertility concerns in young breast cancer patients. Dr. Erica Mayer
-
9:30-9:40 Q&A
-
9:40-10:10 Highlights of ASCO – Metastatic breast cancer. Dr.Hope Rugo
-
10:10-10:20 Q&A
-
10:20-10:50 Escalation and de-escalation strategies in HER2+Breast Cancer. Dr. Javier Cortes
-
10:50-11:00 Q&A
-
11:00-11:15 Break
-
11:15-11:45 Use of CDK4/6i in early and advanced breast cancer patients. Dr. Erica Mayer
-
11:45-11:55 Q&A
-
11:55-12:25 Antibody Drug Conjugates (ADCs) in Breast Cancer. Current and future perspectives. Dr. Hope Rugo
-
12:25-12:35 Q&A
-
12:35-13:30 Round Table Breast Cancer with Drs. Cortes, Rugo, Mayer and LatAm oncologists: Dr. Carlos Barrios (Brazil) and Dr. Mariana Chavez (MD Anderson)
-
Scientific Partner
Sponsors
Supporting
Get in Touch
ASCO DIRECT™ programs are officially licensed by the American Society of Clinical Oncology, Inc. (ASCO). Each presentation is provided solely for educational and informational purposes and personal use only. No part of any presentation may be edited or altered, or reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, nor may it be used for commercial purposes, without in each case the express written permission of ASCO. The ideas and opinions expressed in this presentation do not necessarily reflect those of ASCO. The mention of any company, product, service, or therapy does not constitute an endorsement of any kind by ASCO. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Viewers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify , among other matters, the dosage, the method and duration of administration, or contraindications. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this presentation or any errors or omissions.
© 2024 American Society of Clinical Oncology, Inc. All rights reserved worldwide.